Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)

//Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)

Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)

P.I.: Michelle Ratliffe, MD

Synopsis– The purpose of this study is to see if a high-dose influenza (“flu”) vaccine is able to safely reduce heart or lung-related problems compared to the standard-dose flu vaccine. Both the high dose and standard dose flu vaccines called Fluzone® are manufactured by Sanofi Pasteur.

2017-10-23T20:02:18+00:00October 23rd, 2017|Categories: Clinical Trials|